Biopharma Catalyst Calendar
Forward-looking catalysts for the world's largest pharmaceutical and biotech companies — FDA PDUFA target dates, advisory-committee (AdCom) meetings, and Phase 2/3 clinical-trial readout windows. Trial timing is sourced from ClinicalTrials.gov; each row links to its public source. Updated every few hours.
For informational purposes only — not investment advice. Primary-completion dates are estimates and can precede the investable readout. Open the live Mooboard dashboard →
Companies
This week7
- Aug 7, 2026ClinicalTrials.gov ↗Bimekizumab · Phase 3 · Axial Spondyloarthritis; Ankylosing SpondylitisNCT04436640: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Primary completion 2026-08-07 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 8, 2026ClinicalTrials.gov ↗Yellow fever vaccine (live) · Phase 3 · Yellow Fever ImmunizationNCT07103148: A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population. Primary completion 2026-08-08 (estimated); status RECRUITING.
- Aug 10, 2026ClinicalTrials.gov ↗rozanolixizumab · Phase 2 / Phase 3 · Generalized Myasthenia GravisNCT06149559: A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis. Primary completion 2026-08-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 10, 2026ClinicalTrials.gov ↗Ruxolitinib Cream · Phase 3 · NonSegmental VitiligoNCT06548360: A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo. Primary completion 2026-08-10 (estimated); status RECRUITING.
- Aug 12, 2026ClinicalTrials.gov ↗Enlicitide · Phase 3 · HyperlipidemiaNCT07216482: A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037). Primary completion 2026-08-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 13, 2026ClinicalTrials.gov ↗Crovalimab · Phase 1 / Phase 2 · Paroxysmal Hemoglobinuria, NocturnalNCT03157635: Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria. Primary completion 2026-08-13 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 14, 2026ClinicalTrials.gov ↗Nexium 20mg · Phase 3 · Erosive EsophagitisNCT05267613: Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.. Primary completion 2026-08-14 (estimated); status ACTIVE_NOT_RECRUITING.
Next 30 days47
- Aug 15, 2026ClinicalTrials.gov ↗Fitusiran · Phase 2 / Phase 3 · HemophiliaNCT03974113: Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B. Primary completion 2026-08-15 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 18, 2026ClinicalTrials.gov ↗Rilpivirine · Phase 2 · Human Immunodeficiency Virus Type 1NCT02494986: A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies. Primary completion 2026-08-18 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 18, 2026ClinicalTrials.gov ↗Raludotatug Deruxtecan (R-DXd) · Phase 2 · Gastrointestinal CancerNCT06864169: A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005). Primary completion 2026-08-18 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 19, 2026ClinicalTrials.gov ↗Dazodalibep · Phase 3 · Sjogren's SyndromeNCT06104124: A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity. Primary completion 2026-08-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 20, 2026ClinicalTrials.gov ↗AZD7798 · Phase 2 · Crohn's DiseaseNCT06681324: Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy. Primary completion 2026-08-20 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 21, 2026ClinicalTrials.gov ↗CagriSema (Cagrilintide B and Semaglutide I) · Phase 2 · Diabetes Mellitus, Type 2; Diabetic Peripheral NeuropathyNCT06797869: A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy. Primary completion 2026-08-21 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 21, 2026ClinicalTrials.gov ↗Pembrolizumab · Phase 1 / Phase 2 · Carcinoma, Renal CellNCT04626479: Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A). Primary completion 2026-08-21 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 21, 2026ClinicalTrials.gov ↗Pembrolizumab · Phase 1 / Phase 2 · Carcinoma, Renal CellNCT04626518: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03). Primary completion 2026-08-21 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 23, 2026ClinicalTrials.gov ↗PF-07220060 + PF-07104091 combination dose escalation · Phase 1 / Phase 2 · Breast Cancer; Solid TumorsNCT05262400: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors. Primary completion 2026-08-23 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 24, 2026ClinicalTrials.gov ↗RO7204239 · Phase 2 · Obesity; OverweightNCT06965413: A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity. Primary completion 2026-08-24 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 24, 2026ClinicalTrials.gov ↗AZD9833 · Phase 3 · ER-Positive HER2-Negative Breast CancerNCT04711252: A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. Primary completion 2026-08-24 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 25, 2026ClinicalTrials.gov ↗JDQ443 · Phase 3 · Non-Small Cell Lung CancerNCT05132075: Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. Primary completion 2026-08-25 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 25, 2026ClinicalTrials.gov ↗Rilzabrutinib dose 1 · Phase 2 · Graves' DiseaseNCT06984627: A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease. Primary completion 2026-08-25 (estimated); status RECRUITING.
- Aug 26, 2026ClinicalTrials.gov ↗Satralizumab · Phase 2 · Duchenne Muscular DystrophyNCT06450639: A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD). Primary completion 2026-08-26 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 28, 2026ClinicalTrials.gov ↗Alectinib · Phase 1 / Phase 2 · Non-Small Cell Lung CancerNCT06624059: A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC). Primary completion 2026-08-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 28, 2026ClinicalTrials.gov ↗Giredestrant · Phase 2 · Endometrial CancerNCT05634499: A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer. Primary completion 2026-08-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 28, 2026ClinicalTrials.gov ↗AZD2936 · Phase 1 / Phase 2 · Non-Small-Cell Lung CarcinomaNCT04995523: A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. Primary completion 2026-08-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 30, 2026ClinicalTrials.gov ↗Elranatamab · Phase 3 · Multiple MyelomaNCT06152575: MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide). Primary completion 2026-08-30 (estimated); status RECRUITING.
- Aug 30, 2026ClinicalTrials.gov ↗IBI302 8mg dose · Phase 2 · Neovascular Age-related Macular DegenerationNCT07275840: A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD. Primary completion 2026-08-30 (estimated); status RECRUITING.
- Aug 31, 2026ClinicalTrials.gov ↗Sefaxersen (RO7434656) · Phase 3 · Primary IgA NephropathyNCT05797610: A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression. Primary completion 2026-08-31 (estimated); status RECRUITING.
- Aug 31, 2026ClinicalTrials.gov ↗RSVpreF · Phase 3 · Respiratory Syncytial Virus (RSV)NCT07543380: A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.. Primary completion 2026-08-31 (estimated); status RECRUITING.
- Aug 31, 2026ClinicalTrials.gov ↗BAY3723113 · Phase 3 · Obstructive Hypertrophic CardiomyopathyNCT07023341: A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy. Primary completion 2026-08-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 31, 2026ClinicalTrials.gov ↗zolbetuximab · Phase 2 · Pancreatic Cancer; Metastatic Pancreatic CancerNCT03816163: A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer. Primary completion 2026-08-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 31, 2026ClinicalTrials.gov ↗Trastuzumab deruxtecan · Phase 3 · Gastric Cancer, Adenocarcinoma; Gastroesophageal Junction AdenocarcinomaNCT04704934: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04). Primary completion 2026-08-31 (estimated); status ACTIVE_NOT_RECRUITING.
- Aug 31, 2026ClinicalTrials.gov ↗Staccato alprazolam · Phase 3 · Stereotypical Prolonged SeizuresNCT05077904: A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures. Primary completion 2026-08-31 (estimated); status RECRUITING.
- Sep 2026ClinicalTrials.gov ↗LY3650150 · Phase 3 · Perennial Allergic Rhinitis (PAR)NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1). Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗Tirzepatide · Phase 2 · Overweight; ObesityNCT05536804: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 1, 2026ClinicalTrials.gov ↗NNC0519-0130 · Phase 2 · Chronic Kidney DiseaseNCT06717698: A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease. Primary completion 2026-09-01 (estimated); status RECRUITING.
- Sep 2026ClinicalTrials.gov ↗Adalimumab · Phase 3 · Juvenile Psoriatic ArthritisNCT06100744: A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab. Primary completion 2026-09 (estimated); status RECRUITING.
- Sep 2026ClinicalTrials.gov ↗TOUR006 - 20 MG · Phase 2 · Thyroid Eye DiseaseNCT06088979: A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease. Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 1, 2026ClinicalTrials.gov ↗ARV-471 · Phase 1 / Phase 2 · Breast CancerNCT05548127: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A). Primary completion 2026-09-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗TAF · Phase 2 · Chronic Hepatitis BNCT02932150: Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection. Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗Sacituzumab Govitecan-hziy (SG) · Phase 2 · Non-small Cell Lung CancerNCT05186974: Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗Empasiprubart · Phase 3 · Multifocal Motor Neuropathy (MMN); MMNNCT06742190: A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy. Primary completion 2026-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗SHR-1905 Injection · Phase 2 · Moderate-to-severe Atopic DermatitisNCT07211542: A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis. Primary completion 2026-09 (estimated); status RECRUITING.
- Sep 1, 2026ClinicalTrials.gov ↗Tafasitamab · Phase 3 · Diffuse Large B-cell LymphomaNCT04824092: Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients. Primary completion 2026-09-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗Mitoxantrone hydrochloride liposome injection · Phase 3 · Recurrent Metastatic Nasopharyngeal CarcinomaNCT05717764: Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment. Primary completion 2026-09 (estimated); status NOT_YET_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy · Phase 2 · Gastroesophageal AdenocarcinomaNCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma. Primary completion 2026-09 (estimated); status RECRUITING.
- Sep 2026ClinicalTrials.gov ↗TQB2450+Anlotinib · Phase 3 · Small Cell Lung Cancer Limited StageNCT06469879: A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients. Primary completion 2026-09 (estimated); status NOT_YET_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗NTQ5082 capsules 100 mg · Phase 2 · Primary IgA NephropathyNCT06982040: Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy. Primary completion 2026-09 (estimated); status NOT_YET_RECRUITING.
- Sep 2026ClinicalTrials.gov ↗TQB6411 Injection · Phase 1 / Phase 2 · Esophageal CancerNCT07367516: Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer. Primary completion 2026-09 (estimated); status RECRUITING.
- Sep 2026ClinicalTrials.gov ↗TQA3038 injection/placebo · Phase 1 / Phase 2 · Hepatitis B, ChronicNCT06452693: A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B. Primary completion 2026-09 (estimated); status NOT_YET_RECRUITING.
- Sep 2, 2026ClinicalTrials.gov ↗PF-07868489 · Phase 1 / Phase 2 · Pulmonary Arterial HypertensionNCT06137742: A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension. Primary completion 2026-09-02 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 3, 2026ClinicalTrials.gov ↗SAR441344 IV · Phase 2 · Systemic Lupus ErythematosusNCT05039840: Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus. Primary completion 2026-09-03 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 5, 2026ClinicalTrials.gov ↗Tulisokibart · Phase 2 · Arthritis, RheumatoidNCT07176390: A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014). Primary completion 2026-09-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 5, 2026ClinicalTrials.gov ↗BMS-986490 · Phase 1 / Phase 2 · Advanced Solid TumorsNCT06730750: A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors. Primary completion 2026-09-05 (estimated); status RECRUITING.
- Sep 6, 2026ClinicalTrials.gov ↗IBI306 · Phase 3 · Non-Familial Hypercholesterolemia and Mixed HyperlipidemiaNCT07473960: IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia. Primary completion 2026-09-06 (estimated); status RECRUITING.
31–90 days66
- Sep 15, 2026ClinicalTrials.gov ↗Pembrolizumab · Phase 3 · Endometrial NeoplasmsNCT04634877: Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053). Primary completion 2026-09-15 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 15, 2026ClinicalTrials.gov ↗MET233 and MET097 · Phase 1 / Phase 2 · Obesity and Obesity-related Medical ConditionsNCT06924320: A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes. Primary completion 2026-09-15 (estimated); status RECRUITING.
- Sep 15, 2026ClinicalTrials.gov ↗BAY2599023 (DTX201) · Phase 1 / Phase 2 · Hemophilia ANCT03588299: Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle". Primary completion 2026-09-15 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 15, 2026ClinicalTrials.gov ↗TEV-53408 · Phase 2 · Celiac DiseaseNCT06807463: A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease. Primary completion 2026-09-15 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 17, 2026ClinicalTrials.gov ↗Ocrelizumab Test Formulation · Phase 2 · Multiple SclerosisNCT07074886: A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS). Primary completion 2026-09-17 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 17, 2026ClinicalTrials.gov ↗Biological/Vaccine · Phase 3 · Type 1 Diabetes; Kidney TransplantNCT06832410: An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant. Primary completion 2026-09-17 (estimated); status RECRUITING.
- Sep 18, 2026ClinicalTrials.gov ↗TAK-279 · Phase 2 · Crohn's DiseaseNCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease. Primary completion 2026-09-18 (estimated); status RECRUITING.
- Sep 19, 2026ClinicalTrials.gov ↗Fp/ABS · Phase 3 · AsthmaNCT06664619: A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma. Primary completion 2026-09-19 (estimated); status RECRUITING.
- Sep 22, 2026ClinicalTrials.gov ↗Belzutifan · Phase 1 / Phase 2 · Renal Cell CarcinomaNCT05468697: A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024). Primary completion 2026-09-22 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 22, 2026ClinicalTrials.gov ↗mRNA-1403 · Phase 1 / Phase 2 · Norovirus Acute GastroenteritisNCT05992935: Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age. Primary completion 2026-09-22 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 23, 2026ClinicalTrials.gov ↗PF-07220060 · Phase 2 · Liposarcoma; Prostate CancerNCT04557449: Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors. Primary completion 2026-09-23 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 24, 2026ClinicalTrials.gov ↗YTB323 · Phase 1 / Phase 2 · Systemic Lupus Erythematosus; Lupus NephritisNCT05798117: An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus. Primary completion 2026-09-24 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 24, 2026ClinicalTrials.gov ↗IBI362 · Phase 2 · Obesity; Heart Failure With Preserved Ejection Fraction (HFPEF)NCT06862908: A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity. Primary completion 2026-09-24 (estimated); status RECRUITING.
- Sep 27, 2026ClinicalTrials.gov ↗Litifilimab · Phase 3 · Lupus Erythematosus, SystemicNCT04961567: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus. Primary completion 2026-09-27 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 28, 2026ClinicalTrials.gov ↗AZD0901 · Phase 2 · Gastric Cancer; Gastroesophageal Junction CancerNCT07143604: A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2. Primary completion 2026-09-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 28, 2026ClinicalTrials.gov ↗INCB099280 · Phase 2 · Cutaneous Squamous Cell CarcinomaNCT05888844: A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma. Primary completion 2026-09-28 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 29, 2026ClinicalTrials.gov ↗Amlitelimab · Phase 2 · AsthmaNCT06033833: Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study. Primary completion 2026-09-29 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Glofitamab · Phase 2 · LymphomaNCT04980222: A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Durvalumab · Phase 3 · Non-Small Cell Lung CancerNCT05221840: A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Placebo · Phase 2 · DyslipidaemiaNCT07218900: A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Durvalumab · Phase 3 · Hepatocellular CarcinomaNCT05557838: Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Dato-DXd · Phase 3 · Metastatic Non-small Cell Lung CancerNCT06417814: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Primary completion 2026-09-30 (estimated); status RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗JDQ443 · Phase 1 / Phase 2 · KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small Cell LungNCT05358249: Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗BMS-986449 · Phase 1 / Phase 2 · Advanced Solid TumorsNCT05888831: A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗TAK-279 · Phase 2 · Ulcerative ColitisNCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Litifilimab · Phase 3 · Lupus Erythematosus, SystemicNCT04895241: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Ifinatamab deruxtecan · Phase 1 / Phase 2 · Extensive Stage-small Cell Lung CancerNCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03). Primary completion 2026-09-30 (estimated); status RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Efgartigimod PH20 SC · Phase 2 / Phase 3 · Generalized Myasthenia GravisNCT06392386: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis. Primary completion 2026-09-30 (estimated); status RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Tirzepatide · Phase 1 / Phase 2 · ObesityNCT07000955: Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Pemetrexed · Phase 3 · Non-Small Cell Lung CancerNCT05116462: Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer. Primary completion 2026-09-30 (estimated); status ACTIVE_NOT_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗IBI363+IBI305 · Phase 2 · EGFR Mutant NSCLC and Platinum Resistant Ovarian CancerNCT07124793: A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors. Primary completion 2026-09-30 (estimated); status NOT_YET_RECRUITING.
- Sep 30, 2026ClinicalTrials.gov ↗Dextromethorphan and Bupropion Sustained-Release Tablets · Phase 3 · Major Depressive Disorder (MDD)NCT06958692: A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder. Primary completion 2026-09-30 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Retatrutide · Phase 3 · Type 2 DiabetesNCT06297603: Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3). Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Baricitinib · Phase 3 · Systemic Juvenile Idiopathic ArthritisNCT04088396: A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA). Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 1, 2026ClinicalTrials.gov ↗Ziltivekimab · Phase 3 · Heart Failure; Systemic InflammationNCT06200207: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation. Primary completion 2026-10-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Aflibercept (EYLEA®) · Phase 3 · AMD; nAMDNCT05407636: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD. Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 1, 2026ClinicalTrials.gov ↗Iptacopan (LNP023) · Phase 2 · Age-Related Macular DegenerationNCT05230537: A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration. Primary completion 2026-10-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Sacituzumab Govitecan-hziy · Phase 2 · Solid TumorNCT05119907: Study of Sacituzumab Govitecan in Patients With Solid Tumor. Primary completion 2026-10 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 1, 2026ClinicalTrials.gov ↗efgartigimod PH20 SC · Phase 3 · Primary Immune ThrombocytopeniaNCT04812925: A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia. Primary completion 2026-10-01 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗HRS-9821 Inhalation Suspension · Phase 2 · COPDNCT07640451: A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease. Primary completion 2026-10 (estimated); status NOT_YET_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗SHR-A2102 for Injection · Phase 1 / Phase 2 · Advanced or Metastatic Non-small Cell Lung CancerNCT06512051: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗SHR-A2102 · Phase 2 · Non-small Cell Lung CancerNCT07229729: A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗SHR-A2102；Adebrelimab；Cisplatin · Phase 1 / Phase 2 · Advanced or Metastatic Esophageal CancerNCT06474468: A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2026ClinicalTrials.gov ↗Sirolimus for Injection (Albumin-bound) · Phase 3 · HR+/HER2- Advanced/Metastatic Breast CancerNCT06929325: Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors. Primary completion 2026-10 (estimated); status NOT_YET_RECRUITING.
- Oct 2026ClinicalTrials.gov ↗D-1553 Tablet · Phase 3 · Non Small Cell Lung CancerNCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure. Primary completion 2026-10 (estimated); status RECRUITING.
- Oct 2, 2026ClinicalTrials.gov ↗TAK-861 · Phase 3 · Narcolepsy Type 1 (NT1); Narcolepsy With CataplexyNCT07363720: A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy. Primary completion 2026-10-02 (estimated); status RECRUITING.
- Oct 5, 2026ClinicalTrials.gov ↗KarXT · Phase 3 · Psychosis Associated With Alzheimer's DiseaseNCT05511363: A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1). Primary completion 2026-10-05 (estimated); status RECRUITING.
- Oct 5, 2026ClinicalTrials.gov ↗mRNA-1189 · Phase 1 / Phase 2 · Epstein-Barr Virus InfectionNCT05164094: A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults. Primary completion 2026-10-05 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 6, 2026ClinicalTrials.gov ↗BMS-986278 · Phase 3 · Idiopathic Pulmonary FibrosisNCT06003426: A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis. Primary completion 2026-10-06 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 7, 2026ClinicalTrials.gov ↗Dupilumab · Phase 3 · Atopic DermatitisNCT02612454: Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD). Primary completion 2026-10-07 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 8, 2026ClinicalTrials.gov ↗Hydroxocobalamin Chloride Injection · Phase 3 · Methylmalonic Acidemia (MMA)NCT07163364: A Study to Evaluate the Effects and Safety of Hydroxocobalamin in Participants With Combined Methylmalonic Academia (cblC Type). Primary completion 2026-10-08 (estimated); status NOT_YET_RECRUITING.
- Oct 9, 2026ClinicalTrials.gov ↗Ruxolitinib Cream · Phase 3 · Hidradenitis SuppurativaNCT06959225: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1). Primary completion 2026-10-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 9, 2026ClinicalTrials.gov ↗Ruxolitinib Cream · Phase 3 · Hidradenitis SuppurativaNCT06958211: Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2). Primary completion 2026-10-09 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 11, 2026ClinicalTrials.gov ↗HB1801 · Phase 2 · Advanced Breast CancerNCT07083505: A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer. Primary completion 2026-10-11 (estimated); status NOT_YET_RECRUITING.
- Oct 12, 2026ClinicalTrials.gov ↗Apalutamide · Phase 3 · Metastatic Castrate-sensitive Prostate CancerNCT05884398: A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC. Primary completion 2026-10-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 12, 2026ClinicalTrials.gov ↗CC-92480 · Phase 1 / Phase 2 · Multiple MyelomaNCT05372354: A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma. Primary completion 2026-10-12 (estimated); status RECRUITING.
- Oct 12, 2026ClinicalTrials.gov ↗Ravulizumab · Phase 3 · Paroxysmal Nocturnal HemoglobinuriaNCT05133531: A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment. Primary completion 2026-10-12 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 14, 2026ClinicalTrials.gov ↗Itepekimab (SAR440340) · Phase 3 · Chronic Rhinosinusitis With Nasal PolypsNCT06834347: A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps. Primary completion 2026-10-14 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 15, 2026ClinicalTrials.gov ↗AZD6489 · Phase 1 / Phase 2 · RSV Respiratory Syncytial VirusNCT07717840: A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES). Primary completion 2026-10-15 (estimated); status RECRUITING.
- Oct 15, 2026ClinicalTrials.gov ↗AAA617 · Phase 2 · Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT06894511: An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC. Primary completion 2026-10-15 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 16, 2026ClinicalTrials.gov ↗Glofitamab · Phase 1 / Phase 2 · Non-Hodgkins LymphomaNCT03533283: An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma. Primary completion 2026-10-16 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗PF-07275315 · Phase 2 · Atopic DermatitisNCT05995964: A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis. Primary completion 2026-10-19 (estimated); status RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Deucravacitinib · Phase 3 · Systemic Lupus ErythematosusNCT05617677: A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Deucravacitinib · Phase 3 · Systemic Lupus ErythematosusNCT05620407: A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus. Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Povorcitinib · Phase 3 · Prurigo NodularisNCT06516952: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.
- Oct 19, 2026ClinicalTrials.gov ↗Povorcitinib · Phase 3 · Prurigo NodularisNCT06516965: A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2). Primary completion 2026-10-19 (estimated); status ACTIVE_NOT_RECRUITING.